Catalyst Pharmaceuticals reports Q3 EPS 20c, consensus 19c

Reports Q3 revenue $57.24M, consensus $53.62M. "Catalyst delivered another solid quarter driven by record net revenues that exceeded expectations, marking this as another strong quarter of sequential growth of our FIRDAPSE(R) brand. These results reflect our exceptional commercial execution and continued commitment to the patient community that we serve," said Patrick McEnany, chairman and CEO of Catalyst. "Coupled with sustained organic growth, several significant milestones were achieved during the quarter that further enhance the commercial runway and long-term growth potential for FIRDAPSE(R). The extraordinary execution across all segments of our business underscores our core competencies and adds further confidence that we are on the right path to achieving our long-term goals. With robust year-to-date performance and continued momentum going into the fourth quarter, we are raising our 2022 full year total revenue guidance to $205-210 million."